MindMed (Pharmaceuticals and Biotechnology) Overview
- Year Founded
-
2019
- Status
-
Public
- Employees
-
74
- Stock Symbol
-
MNMD
- Investments
-
3
- Share Price
-
$6.23
- (As of Friday Closing)
MindMed (Pharmaceuticals and Biotechnology) General Information
Description
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
Contact Information
Website
www.mindmed.coCorporate Office
- One World Trade Center
- Suite 8500
- New York, NY 10007
- United States
Corporate Office
- One World Trade Center
- Suite 8500
- New York, NY 10007
- United States
MindMed (Pharmaceuticals and Biotechnology) Timeline
MindMed (Pharmaceuticals and Biotechnology) Stock Performance
As of 25-Apr-2025, MindMed (Pharmaceuticals and Biotechnology)’s stock price is $6.23. Its current market cap is $471M with 75.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.23 | $6.43 | $4.70 - $10.44 | $471M | 75.6M | 1.89M | -$1.54 |
MindMed (Pharmaceuticals and Biotechnology) Financials Summary
As of 31-Dec-2024, MindMed (Pharmaceuticals and Biotechnology) has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 239,416 | 239,416 | 42,110 | (71,853) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (117,427) | (117,427) | (97,234) | (55,111) |
| Net Income | (108,679) | (108,679) | (95,732) | (56,796) |
| Total Assets | 302,151 | 302,151 | 124,541 | 169,993 |
| Total Debt | 21,854 | 21,854 | 14,129 | 0 |
MindMed (Pharmaceuticals and Biotechnology) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
MindMed (Pharmaceuticals and Biotechnology) Comparisons
Industry
Financing
Details
MindMed (Pharmaceuticals and Biotechnology) Competitors (9)
One of MindMed (Pharmaceuticals and Biotechnology)’s 9 competitors is ATAI Life Sciences, a Formerly VC-backed company based in Berlin, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ATAI Life Sciences | Formerly VC-backed | Berlin, Germany | ||||
| Minerva Neurosciences | Formerly VC-backed | Burlington, MA | ||||
| Voyager Therapeutics | Corporation | Lexington, MA | ||||
| ACADIA Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| SAGE Therapeutics | Formerly VC-backed | Cambridge, MA |
MindMed (Pharmaceuticals and Biotechnology) Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
MindMed (Pharmaceuticals and Biotechnology) Patents
MindMed (Pharmaceuticals and Biotechnology) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240285576-A1 | R-mdma for treatment of pain | Pending | 28-Feb-2023 | ||
| US-20240174594-A1 | 4-alkenyl and 4-alkynyl phenethylamine derivatives and related compounds with modified dom-like action | Pending | 30-Nov-2022 | ||
| US-20240010628-A1 | Methods of manufacture of r-mdma | Pending | 08-Jul-2022 | ||
| AU-2023304273-A1 | Methods of manufacture of r-mdma | Pending | 08-Jul-2022 | ||
| US-20230416219-A1 | R-mdma crystal forms | Pending | 25-Jun-2022 | C07D317/50 |
MindMed (Pharmaceuticals and Biotechnology) Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
MindMed (Pharmaceuticals and Biotechnology) Investments & Acquisitions (3)
MindMed (Pharmaceuticals and Biotechnology)’s most recent deal was a Merger/Acquisition with HealthMode for . The deal was made on 26-Feb-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| HealthMode | 26-Feb-2021 | Merger/Acquisition | Other Healthcare Technology Systems | ||
| Broadway Gold Mining | 28-Feb-2020 | Merger/Acquisition | Multi-line Mining | ||
| Coronado Resources (Madison Gold & Copper Mine) | 21-Jul-2016 | Corporate Asset Purchase | Buildings and Property |
MindMed (Pharmaceuticals and Biotechnology) ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
46.63 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,480
Rank
Percentile
Pharmaceuticals
Industry
of 905
Rank
Percentile
Pharmaceuticals
Subindustry
of 435
Rank
Percentile
MindMed (Pharmaceuticals and Biotechnology) Exits (1)
MindMed (Pharmaceuticals and Biotechnology)’s most recent exit was on 21-Jul-2016 from Coronado Resources (Madison Gold & Copper Mine). The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Coronado Resources (Madison Gold & Copper Mine) | 21-Jul-2016 | Completed |
|
MindMed (Pharmaceuticals and Biotechnology) FAQs
-
When was MindMed (Pharmaceuticals and Biotechnology) founded?
MindMed (Pharmaceuticals and Biotechnology) was founded in 2019.
-
Where is MindMed (Pharmaceuticals and Biotechnology) headquartered?
MindMed (Pharmaceuticals and Biotechnology) is headquartered in New York, NY.
-
What is the size of MindMed (Pharmaceuticals and Biotechnology)?
MindMed (Pharmaceuticals and Biotechnology) has 74 total employees.
-
What industry is MindMed (Pharmaceuticals and Biotechnology) in?
MindMed (Pharmaceuticals and Biotechnology)’s primary industry is Drug Discovery.
-
Is MindMed (Pharmaceuticals and Biotechnology) a private or public company?
MindMed (Pharmaceuticals and Biotechnology) is a Public company.
-
What is MindMed (Pharmaceuticals and Biotechnology)’s stock symbol?
The ticker symbol for MindMed (Pharmaceuticals and Biotechnology) is MNMD.
-
What is the current stock price of MindMed (Pharmaceuticals and Biotechnology)?
As of 25-Apr-2025 the stock price of MindMed (Pharmaceuticals and Biotechnology) is $6.23.
-
What is the current market cap of MindMed (Pharmaceuticals and Biotechnology)?
The current market capitalization of MindMed (Pharmaceuticals and Biotechnology) is $471M.
-
Who are MindMed (Pharmaceuticals and Biotechnology)’s competitors?
ATAI Life Sciences, Minerva Neurosciences, Voyager Therapeutics, ACADIA Pharmaceuticals, and SAGE Therapeutics are some of the 9 competitors of MindMed (Pharmaceuticals and Biotechnology).
-
What is MindMed (Pharmaceuticals and Biotechnology)’s annual earnings per share (EPS)?
MindMed (Pharmaceuticals and Biotechnology)’s EPS for 12 months was -$1.54.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
